P792 Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC study

Abstract

Abstract Background Observational real-world evidence (RWE) studies on the effectiveness of ustekinumab (UST) in ulcerative colitis (UC) are needed in addition to RCTs, which may not represent everyday clinical practice. For this reason, the prospective, controlled, propensity score (PS)-adjusted RUN-UC study was conducted on UC patients starting a new biologic therapy with a follow-up period of up to 3 years. The aim of the present analysis was to evaluate the 1-year maintenance therapy effectiveness of UST vs. anti-TNF or vedolizumab (VDZ). Methods Between 2020-2022, 507 UC patients starting a new therapy with UST or other biologics were enrolled in 34 IBD-experienced centres in Germany. After the exclusion of patients with a stoma, small molecules and missing outcomes, the final sample consisted of 476 patients. Response modified (reduction in partial Mayo score (pMayo) by ≥3 points from baseline to month 12 and a reduction of at least 30% or achievement of remission at month 12), clinical remission (CR) (pMayo ≤ 1 plus a bleeding subscore=0) and steroid-free remission (pMayo ≤ 1, bleeding subscore=0 and no systemic use of steroids or oral budesonide use in the previous 8 weeks) were considered as outcomes. To reduce the effect of confounders, PS adjustment with inverse probability of treatment weighting (IPTW) was implemented. Health-related QoL was assessed by using the visual analogue scale (EQ-VAS) of the EQ-5D. Results A total of 476 UC-patients [147 UST (bio-naïve: 12), 168 anti-TNF (ADA: 32.7%, IFX: 59.5%, GOL: 7.7%) (bio-naïve: 114) and 161 VDZ (bio-naïve: 105)] were included in the analysis. The PS-adjustment eliminated systemic differences in the baseline parameters (UST/anti-TNF/VEDO: 42.2/47.0/50.3% males, 25.2/25.0/19.9% EIMs), in particular, the "bio-experienced" characteristic was also equalised, between the groups. Treatment persistence over 12 months was different between UST (93.9%), VDZ (87.0%) and anti-TNF (75.0%) (Fig. 1). The PS-weighted effectiveness of UST (mITT analysis) in terms of response, clinical and steroid-free remission at month 12 (Tab. 1) was comparable to that of anti-TNF and VDZ, as was also the case without PS-weighting (CR: UST 33.1%, anti-TNF 38.5%, VDZ 38.1%). Patients of all treatment groups showed significant improvements in QoL measured as the EQ-VAS after 12 months of treatment. Conclusion In this prospective RUN-UC study with PS-weighted groups, UST showed similar maintenance effectiveness compared to established biologics in UC (anti-TNF and VDZ) with a relatively higher treatment persistence of UST, probably serving as a proxy for effectiveness, suggesting that additional criteria, such as safety and patients´ profile, may play an important role in the selection of biologics.